CS
VBIV

Credit Suisse’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Credit Suisse’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-333
Closed -$28K – 4623
2020
Q4 		$28K Buy
+333
New +$28.4K ﹤0.01% 4289

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Credit Suisse's VBIV Position: Q1 2023 in Review

Credit Suisse held its VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3811.

Credit Suisse first reported a position in VBIV in Q1 2017 and has held it in 18 quarters since. The position peaked at $2.04M in Q3 2020. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

  • Credit Suisse held 0 shares of VBI Vaccines, Inc. New Common Stock (Canada) worth $0 as of Q1 2023.
  • Credit Suisse left its VBI Vaccines, Inc. New Common Stock (Canada) share count unchanged in Q1 2023.
  • VBI Vaccines, Inc. New Common Stock (Canada) made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3811 holding.
  • Credit Suisse first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2017 and has held it in 18 quarters since.
  • Credit Suisse's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $2.04M in Q3 2020.
  • 95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.